NeoStem Inc. (AMEX: NBS)

In a market populated by bright ideas and bold optimism it’s often difficult for a company’s genuine successes to stand out amid a chorus of hyperbole. In fact, it can be most difficult for companies endeavoring in the trenches to have their watershed moments be fully appreciated.

So, when influential columnist Gene Marcial writes a feature article on NeoStem Inc. (AMEX:NBS) that appears in today’s ‘Inside Wall Street’ section of BusinessWeek’s print magazine and on www.BusinessWeek.com highlighting the company’s next generation biomedical services targeting an enormous market for adult stem cell therapeutics and services, it should signal to investors that this company greatly exceeds the run-of-the-mill upstart.  

* * Breaking News from NeoStem * *

Press Release Source: NeoStem, Inc.
Thursday September 6, 11:25 pm ET

NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (AMEX:NBS - News), the first company to specialize in the collection, processing and storage of stem cells from healthy adults for personal use in times of critical medical need, has announced that influential business columnist Gene Marcial has written a feature article on NeoStem that appears in today's BusinessWeek print magazine and on www.BusinessWeek.com that highlight's the Company's next generation biomedical services targeting what the article cites as the projected $8.5 billion market for adult stem cell therapeutics and services.

The BusinessWeek article, which appears in Mr. Marcial's "Inside Wall Street" column, provides additional mainstream media coverage and insight into the Company's position at the forefront of what the Company believes to be a bold new shift in the medical industry where the patient's own body would provide the materials, such as adult stem cells, necessary to formulate potentially lifesaving therapies.

"As the biotechnology industry expands the number of diseases treatable by stem cell therapies, astute institutional investors are buying into businesses that can serve this projected $8.5 billion market," said Mr. Marcial in his column titled "NeoStem Attracts healthy Investment for Stem Cell Services."

Mr. Marcial's article also quotes well-known healthcare venture capitalist and long-time NeoStem investor John Pappajohn, "NeoStem is a leader and an innovator in a burgeoning healthcare category and its value can only be enhanced as it establishes more direct applications for its novel technology."

"We believe the BusinessWeek article provides a fair and accurate description of what we at NeoStem are working very hard to accomplish," said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. "We believe that this high-profile business coverage can only help to serve our shareholders as NeoStem moves towards executing on our mission to become a leader in the coming era of adult stem cell therapeutics."

"With its new capital base, NeoStem is focusing on marketing, sales and business development," continued the BusinessWeek article. "With its processing and storage laboratory in California and a network of collection centers opening across the U.S., a flagship center is on the horizon for New York City, which will gain NeoStem even more attention and revenue. An August 24 research report from Murphy Analytics, a fee-based firm, projects a 12-month target share price of $9.25."

About NeoStem, Inc.
NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal "bio-insurance."

For more information, please visit: www.neostem.com.
For other information and resources about the Company, visit www.CFSG1.com.
For investor specific resources visit http://www.trilogy-capital.com/tcp/neostem/.

Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com

Contact:
NeoStem, Inc.
Robin Smith, Chief Executive Officer, 212-584-4180
rsmith@neostem.com
www.neostem.com
or
Consulting for Strategic Growth 1
Stanley Wunderlich/Daniel Stepanek, 800-625-2236
Fax: 212-337-8089
http://www.cfsg1.com
or
Financial Communications
Trilogy Capital Partners
Ryon Harms, 800-592-6067
ryon@trilogy-capital.com

Source: NeoStem, Inc.
>>>Spacer>>>

About NeoStem

NeoStem, Inc. ("NeoStem" "Neo" "NBS") is a next generation biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. NBS is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells for personal use years or decades later in times of critical medical need.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by storing their own stem cells - providing an accessible supply of healthy, genetically matched stem cells.

Independent market researchers estimate that stem cell therapy sales in the United States are projected to reach more than $700 million by 2010 and $8.5 billion by 2016, based on therapies being investigated. Currently underway are nearly 200 research programs specifically involving the use of autologous adult stem cells – those donated by individuals for their personal use. As the nation’s population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal “bio-insurance.”

Prospective NeoStem customers include: health conscious individuals, persons with genetic risk factors, patients in pre-disease states or early disease states, individuals with job-related risk factors such as radiation exposure, and others. Adult stem cell therapies being investigated include potential treatments of serious injury and illness, such as cancer, heart disease, spinal cord injury, as well as age-related conditions such as Alzheimer’s and macular degeneration, a leading cause of blindness.

Unlike controversial embryonic stem cell technologies, adult stem cells have a 40-year history of successful, real world therapeutic application. Life saving progress in this field has already been made for the treatment of heart disease, lupus, multiple sclerosis, cancer, diabetes and many other critical health problems - currently comprising a patient population of more than 50 million patients in the United States alone.

Neo's service model does not take years of development before generating revenues and thus minimizes the risk related to most long-term biopharmaceutical research and development. Under Management’s strategic initiatives, NeoStem has already begun opening a nationwide network of adult stem cell collection centers, and NeoStem will process and store these stem cells. The collection technologies and processes will be located in existing physician offices and medical facilities, where the procedures can be administered by trusted personal physicians and medical professionals.

...overview...

• NeoStem pioneers the pre-disease collection, processing and storage of stem cells from adult donors 
• NBS is well positioned to be the leading provider of autologous adult stem cells for therapeutic use in regenerative medicine
• NeoStem provides a process that is safe and non-invasive
• NBS uses proprietary technology for the mobilization, processing and multiple use storage
• NeoStem technology with re-infusion does not have the risk of rejection or graft vs. host disease
• NBS IS NOT caught in political policy, debate or religious controversy

NeoStem’s private paying targeted clients 

• Health conscious individuals interested in potential future use of ASC’s in anti-aging and regenerative medicine
• Individuals with disease predisposition because of genetic or current medical risk factors 
• Individuals with disease conditions that are treatable with ASCs.
• BioInsurance policy for the future in the event of a life threatening illness that may be treatable with ASCs 


NeoStem generates revenue from:

• Collections at company-owned sites
• Processing and Storage (recurring revenue)
• Utilization Fee (when cells are used)

NBS will also generate revenues through research grants such as NIH, Foundation and Philanthropic programs.  Sales and marketing efforts to create these revenue networks started in the fourth quarter of 2006 and continued through the first quarter into today. 

NeoStem has two pending U.S. patent applications describing key aspects of our process. These applications address: the process by which NeoStem prepares and stores stem cells collected from the peripheral blood by an apheresis process. the use of stored stem cell to form the basis for medical information that will provide statistics for etiology of disease.
>>>space>>>

* * * What is a Stem Cell ? * * *

A stem cell is a special kind of cell that has the unique capacity to replicate or “self-renew” over a long period of time, often throughout the life of an organism. Under the right conditions or given the right signals, stem cells have the potential to develop into the specialized cells that make up the tissues and organs of the body, such as heart cells, nerve cells and even inner ear hair cells.

Adult stem cells are undifferentiated or unspecialized cells that are found embedded in specialized tissue. Adult stem cells are capable of making identical copies of themselves for the lifetime of the organism. They can form themselves into specialized cells that match the tissues from which they originate, thereby regenerating from within. For example, stem cells taken from bone marrow can give rise to new blood cells even after they are transplanted elsewhere. There is evidence that adult stem cells have even greater potential than this and that they may be used to generate many more cell types than just the cells of the organ from which they were removed. 

>>>Spacer>>>

The Adult Stem Cell Market

By 2010, it is estimated that 39% of the U.S. population (over 110 mm people) will be 45 years of age or older. There is an anticipated rapid increase in age associated diseases and “Bio-Insurance” - banking someones own stem cells for future use to treat a disease - will become BIG BUSINESS.

Other Recent News From NeoStem

Press Release Source: NeoStem, Inc.
Friday August 24, 4:01 pm ET

NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (AMEX:NBS - News), the first company to specialize in the collection, processing and storage of stem cells from healthy adults for personal use in times of critical medical need, announced that Murphy Analytics (MA), a fee-based equity research firm, has issued a research report update that projects a 12-month target share price of $9.25 citing the Company's improved financial position, strong senior management team and its recent listing on the American Stock Exchange.

"With capital and key personnel in place, NBS may now focus on marketing, sales and business development - driving business through the existing collection agreements, and building the collection infrastructure," said the Murphy Analytics Report, written by Patrick Murphy, C.F.A. "With the capital to implement a multi-faceted direct to consumer marketing campaign, NBS customer acquisition should begin in earnest over the next few quarters, driven initially by existing collection agreements."

"We are pleased for this report to be readily available for all our current shareholders as well as for potential investors," said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. "Although paid for by the Company, NeoStem's management believes the report presents a balanced view and is pleased that Murphy Analytics has generated this institutional-quality report."

According to the report, "MA is affirming a 12-month target price of $9.25, adjusted for the August 2007 reverse stock split."

NeoStem's proprietary technology positions the company at the forefront of a bold new shift in the medical industry where the patient's own body would provide the materials, such as adult stem cells, necessary to formulate therapies that have, until recently, been provided by pharmaceutical companies in the form of synthetic, chemically engineered drugs.

NeoStem has already begun opening a nationwide network of adult stem cell collection centers. The stem cells are collected by a trusted physician and the process is minimally invasive involving a shot of Neupogen in the days before collection that causes stem cells to rapidly enter the blood stream; blood is then drawn; a separation of the stem cells from other blood components through a process called apheresis occurs; and then the immediate return of such blood components to the self donor. It is a relatively easy procedure that takes approximately 3 hours, but provides patients with the peace-of-mind of knowing that they will have their own, healthy adult stem cells should the need arise.

The full report is available free of charge to all interested investors HERE  
You may view this entire news release HERE

NEW YORK—August 17, 2007 -- NeoStem, Inc. (AMEX: NBS), the first company to specialize in the collection, processing and storage of stem cells from healthy adults for personal use in times of critical medical need, announced today that it has filed a far-reaching patent application that initiates the process of safeguarding the Company’s proprietary procedures for collecting, storing and developing potential biotherapies from adult stem cells derived from a patient’s own body. The application encompasses several groundbreaking concepts that include next generation biomedical services such as bio-insurance and the formulation of designer stem cell-related therapies for healthy individuals interested in mitigating potential health conditions in the future.

NeoStem’s proprietary technology positions the company at the forefront of a bold new shift in the medical industry where the patient’s own body would provide the materials, such as adult stem cells, necessary to formulate therapies that have, until recently, been provided by pharmaceutical companies in the form of synthetic, chemically engineered drugs.

"We believe NeoStem is positioned to take a leadership role in the emerging stem cell therapeutic market by fractionating the cells for the treatment of different diseases in what many medical doctors and scientists believe to be the next great revolution in medicine," said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. "We believe we are at the threshold of stem cells being a mainstream therapeutic that will dramatically change how medicine is practiced in the future. NeoStem is firmly committed to protect and continue to build a robust portfolio of pending patents as a means to securing long-term value for our shareholders."

NeoStem’s first-to-market competitive advantage uniquely positions the Company to capitalize on the hundreds of adult stem cell-based clinical therapy trials currently underway. As these stem cell-based therapies become available, NeoStem clients will be among the first to benefit from the life saving progress that has already been made for such debilitating conditions as cancer, heart disease, multiple sclerosis, lupus, and many others. 

"It is important for investors to understand that we believe that our proprietary technology positions us above and beyond the processes currently being employed by cord blood banks, which simply inject the entire spectrum of stem cells without regard to the specific disease target," said Denis Rodgerson, Ph.D., Director of Stem Cell Science of NeoStem. "We believe that the NeoStem service offering will prove to be heads and shoulders above any other stem cell services company."

The NeoStem process begins when a physician or health industry professional identifies a individual who could benefit from having their stem cells collected and banked. Candidates for bio-insurance include a broad range of adults, including health conscious individuals, someone with genetic risk factors, or patients in early-disease states. Once the physician has extracted the patient’s stem cells from peripheral blood (through a non-invasive, easy-to-administer process) the stem cells are sent to a NeoStem facility to be cryopreserved, stored and characterized. If the need arises in the future, NeoStem clients may benefit from prompt access to therapeutically useful, genetically matched adult stem cells. NeoStem generates revenues from every stage of that process. MORE

Press Release Source: NeoStem, Inc.
Tuesday August 14, 4:23 pm ET

NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (AMEX:NBS - News), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, today announced completion of its second closing of its public offering generating $1 million in gross proceeds. Together with the gross proceeds of the first closing of the public offering on August 9, 2007, the Company has raised an aggregate of approximately $6.3 million.

The public financing was comprised of 1,270,000 units with each unit consisting of one share of common stock and one-half of a five year Class A warrant to purchase one-half a share of common stock at a price of $6 per share.

You May View the Entire news Release HERE

NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (OTCBB:NEOI - News), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, today announces its common stock and units have been approved to be listed on the American Stock Exchange under the ticker symbols--NBS and NBS.U--and will start trading August 9, 2007. The listing followed the completion of a public-offering in excess of $5 million and a one-for-ten reverse stock split.

The listing on the American Stock Exchange is consistent with the Company's strategic mission to attract institutional investors and to provide long-term value for its shareholders.

"We are extremely proud of our recent achievements and of surpassing yet another milestone for the benefit of our shareholders," said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. "It is an honor to be listed on the American Stock Exchange and to enjoy all the benefits of its long and storied history. We believe these recent developments will be major catalysts as we move forward into a position of leadership in the burgeoning market for stem cell therapies and services."

The closing of this offering is the latest validation of NeoStem's high-growth business model focused on developing next generation services and therapies that have the potential to help millions of health-conscious individuals. The total offering comprises units at a price of $5 per unit. Each unit consists of one share of common stock and one-half a Class A warrant to purchase one-half a share of common stock. Thus, 1,000 units consist of 1,000 shares and warrants to purchase 500 shares of common stock.

You May View the Entire news Release HERE
a

Financial Highlights For NeoStem

• NeoStem has the first to market advantage in the collection and storage of stem cells extracted from adults
• NeoStem represents a high growth opportunity in a large growing market
• NeoStem is well positioned with industry leaders and academic institutions
• NeoStem has an attractive valuation compared to other stem cell related companies

To Contact NeoStem

---

***The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid fifteen thousand dollars by Trilogy Capital Partners for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.